Pomegra
UnitedHealth Group delivered better-than-expected fourth quarter results on January 27, demonstrating resilience amid persistent medical cost inflation that has pressured the healthcare sector throughout 2025. The health insurance giant reported adjusted earnings per share of $2.18, beating analyst estimates by 4.3%, while quarterly revenue of $114.2 billion exceeded consensus projections by $400 million.
Strong Revenue Growth Masks Margin Compression
The company achieved 12.7% year-over-year revenue growth in the fourth quarter, driven primarily by membership expansion across its UnitedHealthcare insurance segment and continued growth in its Optum healthcare services division. Total membership reached 57.2 million people, representing a net addition of 1.8 million members compared to the previous quarter.
However, medical cost ratios remained elevated at 89.2% for the quarter, reflecting ongoing challenges from higher utilization rates and inflationary pressures in healthcare services. This represented a 380 basis point increase from the same period in 2024, when the medical cost ratio stood at 85.4%.
Optum Division Provides Stability
UnitedHealth's Optum healthcare services segment generated $71.8 billion in revenue for the quarter, up 8.4% year-over-year, providing crucial diversification benefits as insurance margins faced pressure. The division's operating margin of 7.2% helped offset some of the headwinds in the traditional insurance business.
OptumHealth's value-based care arrangements now serve over 6.5 million patients, while OptumRx processed 1.4 billion prescriptions during 2025, maintaining its position as one of the nation's largest pharmacy benefit managers.
2026 Guidance Reflects Cautious Optimism
Management provided 2026 full-year earnings guidance of $27.50 to $28.50 per share, representing the midpoint estimate of $28.00, which aligns with current analyst expectations. The company projects revenue growth of 6-8% for 2026, anticipating continued membership growth while medical cost trends gradually moderate.
Chief Executive Officer Andrew Witty emphasized the company's focus on managing medical cost inflation through enhanced care coordination and value-based partnerships with providers. The company expects medical cost ratios to improve gradually throughout 2026 as utilization patterns normalize.
Market Reaction and Trading Activity
UnitedHealth shares gained 2.8% in pre-market trading following the earnings announcement, with trading volume reaching 1.2 million shares before the market open. The stock has faced headwinds throughout 2025, declining 8.3% year-to-date as investors remained concerned about medical cost pressures across the health insurance sector.
Wall Street analysts maintain largely positive sentiment, with 17 buy ratings, 8 holds, and 2 sell ratings among major investment firms. The average price target stands at $393.77, implying upside potential of approximately 11.7% from current levels.
UnitedHealth's fourth quarter performance demonstrates the company's ability to navigate challenging market conditions while maintaining growth momentum. The combination of membership expansion, diversified revenue streams through Optum, and disciplined cost management positions the healthcare giant for gradual margin recovery as medical cost inflation moderates in 2026.
Mentioned tickers: UNH
